Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 at the upcoming 15^th International Congress of Inborn Errors of Metabolism (ICIEM) being held September 2-6, 2025 in Kyoto, Japan.

Read more at globenewswire.com